Community Communications

May 2024 – FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001)

March 2024 – Delpacibart Etedesiran (AOC 1001) MARINA-OLE™ Long-term Data and Phase 3 HARBOR Study

December 2023 – AOC 1044 Healthy Volunteer Data Update

October 2023 – AOC 1001 Data Update

 

Clinical Studies

 

HARBOR™ is a randomized, placebo-controlled, double blind Phase 3 clinical trial to evaluate del-desiran (AOC 1001) in people living with DM1. For more information on this study click here or visit http://www.clinicaltrials.gov and search for NCT06411288.

 


MARINA-OLE™ is an open-label, multi-center trial designed to evaluate the long-term safety and tolerability of del-desiran in participants with DM1 who were previously enrolled in the MARINA® Phase 1/2 trial. For more information on this study click here or visit http://www.clinicaltrials.gov and search for NCT05479981.

 


The EXPLORE44™ trial is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial to evaluate AOC 1044 in healthy volunteers and participants with DMD mutations amenable to exon 44 skipping (DMD44). For more information on this study click here or visit www.clinicaltrials.gov and search for NCT05670730.

 


The FORTITUDE™ trial is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial designed to evaluate single and multiple doses of AOC 1020 in approximately 70 adult participants with facioscapulohumeral muscular dystrophy (FSHD). For more information on this study click here or visit http://www.clinicaltrials.gov and search for NCT05747924.